Indications de l'autogreffe dans la sclérose en plaques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) en lien avec la Société francophone de la sclérose en plaques
Zephir, H.; Puyade, M.; Gueguen, A.et al.
2019 • In Bulletin du Cancer, 106 (Suppl. 1), p. 92-101
Sclérose en plaques; Autogreffe; Cellules souches hématopoïétiques; Recommandations
Abstract :
[fr] Dans une démarche qui vise à uniformiser les procédures d'allogreffe et d'autogreffe de cellules
souches hématopoïétiques, la Société francophone de greffe de moelle et thérapie cellulaire (SFGM-TC) a organisé les huitièmes ateliers d'harmonisation des pratiques en allogreffe de cellules souches hématopoïétiques en septembre 2017 à Lille. Dans le contexte de cet atelier, il a été développé et mis à jour les indications et le suivi des autogreffes de cellules souches hématopoïétiques dans la sclérose en plaques sous l'égide de la SFGM-TC et de la Société francophone de la sclérose en plaques.
Disciplines :
Hematology
Author, co-author :
Zephir, H.; CHU de Lille, université de Lille, pôle des neurosciences et de l'appareil locomoteur, LIRIC (Lille Inflammation Research International Center) UMR 995, rue Emile-Laine, Lille, 59000, France
Puyade, M.; CHU de Poitiers, service de médecine interne, 2, rue de la Milétrie, Poitiers cedex, 86021, France
Gueguen, A.; Fondation A.-de Rothschild, service de neurologie, 25, rue Manin, cedex 19, Paris, 75940, France
Michel, Laure
Terriou, L.; CHRU, hôpital Claude-Huriez, service des maladies du sang, rue Michel-Polonovski, Lille cedex, 59037, France
Dive, Dominique ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Laureys, G.; University hospital Ghent, department of neurology, De Pintelaan 185, Ghent, 9000, Belgium
Mathey, G.; CHRU de Nancy, hôpital Central, service de neurologie, 29, avenue du Maréchal-de-Lattre-de-Tassigny, Nancy cedex, 54035, France
Labauge, P.; CHU de Montpellier, hôpital Gui-de-Chauliac, centre de ressources et de compétences sclérose en plaques, 80, avenue Augustin-Fliche, cedex 5, Montpellier, 34295, France
Marjanovic, Z.; AP–HP, hôpital Saint-Antoine, hématologie clinique et thérapie cellulaire, 184, rue du Faubourg-Saint-Antoine, cedex 12, Paris, 75571, France
Pugnet, G.; CHU de Toulouse, hôpital Purpan, service de médecine interne, 1, place Baylac, Toulouse, 31059, France
Badoglio, M.; Hôpital Saint-Antoine, EBMT Data Office, 184, rue du Faubourg-Saint-Antoine, cedex 12, Paris, 75571, France
Lansiaux, P.; Hôpital Saint-Louis, centre de référence des maladies auto-immunes systémiques rares d’Île-de-France, filière FAI2R, IUH EA-3518, UF04, unité de médecine interne, maladies auto-immunes et pathologie vasculaire, 1, avenue Claude-Vellefaux, Paris, 75475, France
Ibrahim, Y.-A.; CHU de Lille, université de Lille 2, LIRIC Inserm U995, Lille, 59000, France
Indications de l'autogreffe dans la sclérose en plaques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) en lien avec la Société francophone de la sclérose en plaques
Mikaeloff, Y., et al. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 130:Pt 10 (2007), 2589–2595.
Ascherio, A., Munger, K.L., 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Epstein-Barr virus and multiple sclerosis: epidemiological evidence. Clin Exp Immunol 60:1 (2010), 120–124.
Ascherio, A., Munger, K.L., Simon, K.C., Vitamin D and multiple sclerosis. Lancet Neurol 9:6 (2010), 599–612.
Patsopoulos, N.A., et al. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet, 9(11), 2013, e1003926.
Confavreux, C., Vukusic, S., Age at disability milestones in multiple sclerosis. Brain 129:Pt 3 (2006), 595–605.
Scalfari, A., et al. Age and disability accumulation in multiple sclerosis. Neurology 77:13 (2011), 1246–1252.
Leray, E., et al. Excess mortality in patients with multiple sclerosis starts at 20 years from clinical onset: data from a Large-Scale French Observational Study. PLoS One, 10(7), 2015, e0132033.
Fromont, A., et al. Geographic variations of multiple sclerosis in France. Brain 133:Pt 7 (2010), 1889–1899.
Kurtzke, J.F., Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:11 (1983), 1444–1452.
Giovannoni, G., et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. Mult Scler Relat Disord 4:4 (2015), 329–333.
Sormani, M.P., et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis. Neurology 88:22 (2017), 2115–2122.
Edan, G., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:2 (1997), 112–118.
Hartung, H.P., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:9350 (2002), 2018–2025.
Fassas, A., et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 20:8 (1997), 631–638.
Mancardi, G.L., et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57:1 (2001), 62–68.
Burt, R.K., Kozak, T., Hematopoietic stem cell transplantation for multiple sclerosis: finding equipoise. Bone Marrow Transplant 320:Suppl. 1 (2003), S45–S48.
Saiz, A., et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology 62:2 (2004), 282–284.
Burt, R.K., et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 8:3 (2009), 244–253.
Nash, R.A., et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102:7 (2003), 2364–2372.
Saccardi, R., et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 12:6 (2006), 814–823.
Muraro, P.A., et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol 13:7 (2017), 391–405.
Polman, C.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:9 (2006), 899–910.
Coles, A.J., et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:9856 (2012), 1829–1839.
Cohen, J.A., et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:9856 (2012), 1819–1828.
Lee, P., et al. A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57:2 (2013), 141–146.
Olerup, O., et al. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 108:3 (1995), 870–878.
Haines, J.L., et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum Mol Genet 7:8 (1998), 1229–1234.
Muraro, P.A., et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 201:5 (2005), 805–816.
Muraro, P.A., et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest 124:3 (2014), 1168–1172.
Darlington, P.J., et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 73:3 (2013), 341–354.
Abrahamsson, S.V., et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 136:Pt 9 (2013), 2888–2903.
Arruda, L.C.M., et al. Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation. Clin Immunol 169 (2016), 47–57.
Carreras, E., et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 88:3 (2003), 306–314.
Saccardi, R., et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105:6 (2005), 2601–2607.
Samijn, J.P., et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 77:1 (2006), 46–50.
Shevchenko, J.L., et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol 40:11 (2012), 892–898.
Openshaw, H., et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 6:5A (2000), 563–575.
Burt, R.K., et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102:7 (2003), 2373–2378.
Atkins, H.L., et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 388:10044 (2016), 576–585.
Mancardi, G.L., et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 84:10 (2015), 981–988.
Mancardi, G.L., et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 18:6 (2012), 835–842.
Burman, J., et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 85:10 (2014), 1116–1121.
Muraro, P.A., et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol 74:4 (2017), 459–469.
Reston, J.T., et al. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler 17:2 (2011), 204–213.
Li, C., et al. Efficacy of hematopoietic stem cell formultiple sclerosis, an evidence based meta-analysis. Cell Mol Biol (Noisy-le-grand) 62:4 (2016), 48–52.
Alexander, T., et al. SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. Bone Marrow Transplant 50:2 (2015), 173–180.
Snowden, J.A., et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47:6 (2012), 770–790.
Pasquini, M.C., et al. Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant 16:8 (2010), 1076–1083.
Tipton, R., Yakoub-Agha, I., [How we harmonize HSCT clinical practices among the SFGM-TC centers]. Bull Cancer 103:11S (2016), S193–S197.
Polman, C.H., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:2 (2011), 292–302.
Drake, A.S., et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler 16:2 (2010), 228–237.
Benedict, R.H., et al. Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurol, 12, 2012, 55.
Kragt, J.J., et al. Clinical impact of 20 % worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 12:5 (2006), 594–598.
Plavina, T., et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:6 (2014), 802–812.
Pugnet, G., et al. Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bull Cancer 104:12S (2017), S169–S180, 10.1016/j.bulcan [Epub 2017 Nov 22. Review. French.].
